Displaying 41 - 60 of 350
FTC Releases Interim Staff Report on Prescription Drug Middlemen
Date
The Federal Trade Commission today published an interim report on the prescription drug middleman industry that underscores the impact pharmacy benefit managers (PBMs) have on the accessibility and...
FTC Submits Comment Supporting Proposed USPTO Rule
Date
The Federal Trade Commission today submitted a comment supporting a proposed U.S. Patent and Trademark Office (USPTO) rule involving the disclosure of patent settlement agreements. In April, the USPTO...
FTC Expands Patent Listing Challenges, Targeting More Than 300 Junk Listings for Diabetes, Weight Loss, Asthma and COPD Drugs
Date
Today, the Federal Trade Commission expanded its campaign against pharmaceutical manufacturers’ improper or inaccurate listing of patents in the Food and Drug Administration’s (FDA) Orange Book...
FTC, HHS Extend Public Comment Period on Generic Drug Shortages and Competition Request for Information
Date
The Federal Trade Commission and the U.S. Department of Health and Human Services (HHS) are extending the deadline for the public to comment on a joint Request for Information (RFI) that seeks to...
FTC, HHS Seek Public Comment on Generic Drug Shortages and Competition Amongst Powerful Middlemen
Date
Today the Federal Trade Commission (FTC) and the U.S. Department of Health and Human Services (HHS) jointly issued a Request for Information to understand how the practices of two types of...
FTC Submits Comment on March-In Rights to Promote Efforts to Lower Drug Prices
Date
Today the Federal Trade Commission issued a comment in response to the National Institute of Standards and Technology’s (NIST) request for information on its Draft Interagency Guidance Framework for...
Statement on Second Circuit Order Upholding “Pharma Bro” Martin Shkreli’s Lifetime Ban
Date
Today, the United States Court of Appeals for the Second Circuit affirmed a district court ruling which ordered “Pharma Bro” Martin Shkreli to face a lifetime ban from participating in the...
Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter In the Matter of Sanofi/Maze Therapeutics
Date
By
Lina M. Khan, Former Chair and Commissioner;
Rebecca Kelly Slaughter, Former Commissioner
Matter Number
D09422
File
Text of Statement
(126.92 KB)
Sanofi/Maze Therapeutics, Inc., In the Matter of
On December 13, 2023, the FTC moved to dismiss its case challenging the transaction following Sanofi’s decision to terminate its transaction with Maze Therapeutics Inc.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
2310091
Docket Number
9422
Case Status
Closed
FTC Approves Final Order Settling Horizon Therapeutics Acquisition Challenge
Date
The Federal Trade Commission today finalized a consent order that resolves potential competitive harm stemming from Amgen Inc.’s acquisition of Horizon Therapeutics plc. As part of a nationwide...
Amgen, Inc. and Horizon Therapeutics plc, In the Matter of
In August 2023, the FTC reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc. As part of a nationwide settlement of their challenge to the acquisition, the FTC and attorneys general from six states – California, Illinois, Minnesota, New York, Washington, and Wisconsin – also dismissed the related federal court preliminary injunction action, allowing the transaction to proceed, with the conditions imposed by the order. In December 2023, the FTC finalized the consent order with Amgen Inc. and appointed a monitor.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
231 0037
Docket Number
9414
Case Status
Closed
Statement Regarding the Termination of Sanofi’s Proposed Acquisition of Maze Therapeutics’ Pompe Disease Drug
Date
Following Sanofi’s decision to terminate its proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s developmental drug to treat Pompe disease, the Federal Trade Commission moved to...
FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that Threatens Sanofi’s Monopoly
Date
The Federal Trade Commission is seeking to block Sanofi’s proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s therapy in development for treatment of Pompe disease. The Commission...
Mylan Pharmaceuticals, et al. v. Sanofi-Aventis, et al.
Date
Citation Number
2:23-cv-00836-MRH
Federal Court
Western District of Pennsylvania
File
FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by Improper Orange Book Listings
Date
The Federal Trade Commission filed an amicus brief to address the anticompetitive harm that stems from improperly listed patents in the Food and Drug Administration’s (FDA) publication of “Approved...
FTC Challenges More Than 100 Patents as Improperly Listed in the FDA’s Orange Book
Date
Today, the Federal Trade Commission (FTC) challenged more than 100 patents held by manufacturers of brand-name asthma inhalers, epinephrine autoinjectors, and other drug products as improperly or...
Displaying 41 - 60 of 350